Swedish biotechnology company Cantargia AB (STO:CANTA) on Monday reported positive results from two clinical trials evaluating nadunolimab in combination therapy for cancer patients.
The data suggest that nadunolimab may be effective in patients who have progressed on pembrolizumab treatment, particularly those with a specific profile of immune and immunosuppressive cells in the tumour microenvironment. The clinical trials demonstrated encouraging median survival times and disease control rates in these patients.
Cantargia said that the findings highlight the potential of nadunolimab for patients with limited treatment options after progressing on immunotherapy.
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment